Bio-Path Holdings Management

Management criteria checks 3/4

Bio-Path Holdings' CEO is Peter Nielsen, appointed in Jan 2007, has a tenure of 17.33 years. total yearly compensation is $827.12K, comprised of 69.5% salary and 30.5% bonuses, including company stock and options. directly owns 0.083% of the company’s shares, worth €2.58K. The average tenure of the management team and the board of directors is 17.3 years and 8 years respectively.

Key information

Peter Nielsen

Chief executive officer

US$827.1k

Total compensation

CEO salary percentage69.5%
CEO tenure17.3yrs
CEO ownership0.08%
Management average tenure17.3yrs
Board average tenure8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Peter Nielsen's remuneration changed compared to Bio-Path Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$14m

Dec 31 2023US$827kUS$575k

-US$16m

Sep 30 2023n/an/a

-US$17m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$16m

Dec 31 2022US$1mUS$555k

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$1mUS$530k

-US$10m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$1mUS$510k

-US$11m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$735kUS$490k

-US$9m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$672kUS$490k

-US$9m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$10m

Dec 31 2017US$594kUS$475k

-US$8m

Compensation vs Market: Peter's total compensation ($USD827.12K) is above average for companies of similar size in the German market ($USD385.89K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


CEO

Peter Nielsen (74 yo)

17.3yrs

Tenure

US$827,117

Compensation

Mr. Peter H. Nielsen, MBA, is a Co-Founded Bio-path Holdings, Inc. in 2007 and has been its Chairman, President, Chief Executive Officer, Chief Financial Officer and Treasurer since 2008. Mr. Nielsen licen...


Leadership Team

NamePositionTenureCompensationOwnership
Peter Nielsen
Co-Founder17.3yrsUS$827.12k0.083%
€ 2.6k
Douglas Morris
Co-Founder17.3yrsUS$89.98k0%
€ 0
Michael Hickey
VP of Clinical Operations1.3yrsno datano data
Anthony Price
Senior Vice President of Financeno datano datano data
Ana Ashizawa
Senior Vice President of Researchno datano datano data

17.3yrs

Average Tenure

Experienced Management: IBP0's management team is seasoned and experienced (17.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter Nielsen
Co-Founder16.3yrsUS$827.12k0.083%
€ 2.6k
Douglas Morris
Co-Founder17.3yrsUS$89.98k0%
€ 0
Jorge Cortes
Chairman of the Scientific Advisory Board8.8yrsno datano data
Paul Aubert
Independent Director6.3yrsUS$73.81k0%
€ 0
Jason Fleming
Member of the Scientific Advisory Board5.8yrsno datano data
Heath Cleaver
Independent Director10.3yrsUS$85.31k0%
€ 0
D. Hooper
Member of the Scientific Advisory Board7.3yrsno datano data
Aline Sherwood
Independent Director2.2yrsUS$76.81k0%
€ 0

8.0yrs

Average Tenure

53yo

Average Age

Experienced Board: IBP0's board of directors are considered experienced (8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/21 02:12
End of Day Share Price 2024/02/22 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Path Holdings, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertMaxim Group
Pamela BassettMaxim Group
Raghuram SelvarajuRodman & Renshaw, LLC